Regeneron says IDMC recommends halt of some REGN-COV2 trial enrollment for safety risks - MarketWatch

1. Regeneron says IDMC recommends halt of some REGN-COV2 trial enrollment for safety risks  MarketWatch
2. COVID toes update: Analysis finds symptoms could last months  TODAY
3. Study finds 20 percent of grocery workers had COVID-19, most without symptoms  New York Post
4. For 2nd time, study testing COVID-19 antibody drug has setback  WAPT Jackson
5. Regeneron suspends COVID-19 antibody trial among sickest patients  Medical Xpress
6. View Full Coverage on Google News

(CLICK HERE TO READ AND SEE MORE)